Log in

Progenics Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PGNX)

$4.81
-0.24 (-4.75 %)
(As of 10/24/2019 01:20 AM ET)
Today's Range
$4.79
Now: $4.81
$5.12
50-Day Range
$4.36
MA: $5.15
$5.69
52-Week Range
$3.42
Now: $4.81
$6.31
Volume810,900 shs
Average Volume1.11 million shs
Market Capitalization$416.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.79
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.62 million
Book Value$1.20 per share

Profitability

Net Income$-67,660,000.00
Net Margins-339.86%

Miscellaneous

Employees79
Market Cap$416.65 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.


Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.02. The biotechnology company earned $9.97 million during the quarter, compared to analyst estimates of $6.40 million. Progenics Pharmaceuticals had a negative net margin of 339.86% and a negative return on equity of 65.17%. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 analysts have issued 1 year price targets for Progenics Pharmaceuticals' shares. Their predictions range from $6.50 to $14.00. On average, they anticipate Progenics Pharmaceuticals' share price to reach $10.17 in the next twelve months. This suggests a possible upside of 111.4% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

What is the consensus analysts' recommendation for Progenics Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

Has Progenics Pharmaceuticals been receiving favorable news coverage?

Media headlines about PGNX stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a news impact score of 0.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Progenics Pharmaceuticals.

Are investors shorting Progenics Pharmaceuticals?

Progenics Pharmaceuticals saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 10,410,000 shares, a drop of 5.5% from the August 30th total of 11,020,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is presently 8.6 days. Approximately 13.4% of the company's stock are sold short. View Progenics Pharmaceuticals' Current Options Chain.

Who are some of Progenics Pharmaceuticals' key competitors?

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Vonage (VG), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Portola Pharmaceuticals (PTLA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and Opko Health (OPK).

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark R. Baker, CEO & Director (Age 64)
  • Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
  • Mr. Benedict Osorio, Chief Operating Officer (Age 62)
  • Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
  • Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)

Who are Progenics Pharmaceuticals' major shareholders?

Progenics Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhumbline Advisers (0.30%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View Institutional Ownership Trends for Progenics Pharmaceuticals.

Which institutional investors are buying Progenics Pharmaceuticals stock?

PGNX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Rhumbline Advisers. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc and Velan Capital, LP. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $4.81.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $416.65 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.

What is Progenics Pharmaceuticals' official website?

The official website for Progenics Pharmaceuticals is http://www.progenics.com/.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]


MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  369 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  691
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel